DarioHealth (DRIO) Cash & Equivalents (2012 - 2026)

DarioHealth's Cash & Equivalents history runs 15 years deep, the most recent figure standing at $15.0 million for Q1 2026.

• Quarterly Cash & Equivalents fell 46.23% year-over-year to $15.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.0 million (down 46.23% YoY) and the FY2025 annual result came in at $21.8 million, down 21.47% from the prior year.
• Cash & Equivalents was $15.0 million for Q1 2026 at DarioHealth, down from $21.8 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $67.9 million in Q2 2022 and bottomed at $15.0 million in Q1 2026.
• A 5-year average of $36.5 million and a median of $34.4 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2024 — Cash & Equivalents sank 64.57% — and 2025, when it jumped 105.23%.
• DarioHealth's Cash & Equivalents stood at $49.4 million in 2022, then dropped by 25.45% to $36.8 million in 2023, then declined by 24.55% to $27.8 million in 2024, then decreased by 21.47% to $21.8 million in 2025, then plunged by 31.31% to $15.0 million in 2026.
• Business Quant data shows DRIO's Cash & Equivalents at $15.0 million in Q1 2026, $21.8 million in Q4 2025, and $31.9 million in Q3 2025.